| Serial Number | 87953650 |
| Word Mark | BAUSCH HEALTH |
| Filing Date | Friday, June 8, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 21, 2021 |
| Registration Number | 6598161 |
| Registration Date | Tuesday, December 21, 2021 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, January 29, 2019 |
| Description of Mark | The mark consists of the word "BAUSCH" in gray. The "H" in "BAUSCH" has an extended horizontal center forming a cross in which in the center of the cross is a blue square. The word "HEALTH" follows "BAUSCH" and appears in blue and lowercase, except the first letter "H". The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark. |
| Goods and Services | Pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; antiviral pharmaceutical compounds; antiobesity agent in the nature of a pharmaceutical preparation; Dermotherapeutic preparation for use in the treatment of obesity; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; Pharmaceutical preparations, namely, a topical cream for the treatment of pre-cancerous skin lesions; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of a neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness |
| Indication of Colors claimed | The color(s) gray and blue is/are claimed as a feature of the mark. |
| NOT AVAILABLE | "HEALTH" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 14, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | Wednesday, March 12, 2014 |
| First Use In Commerce Date | Wednesday, March 12, 2014 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Event Date | Event Description |
| Wednesday, August 15, 2018 | ASSIGNED TO EXAMINER |
| Tuesday, June 12, 2018 | NEW APPLICATION ENTERED |
| Thursday, June 14, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 15, 2018 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, August 15, 2018 | NON-FINAL ACTION WRITTEN |
| Wednesday, August 15, 2018 | NON-FINAL ACTION E-MAILED |
| Wednesday, August 15, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, September 22, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, September 22, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, September 24, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 4, 2018 | NON-FINAL ACTION WRITTEN |
| Thursday, October 4, 2018 | NON-FINAL ACTION E-MAILED |
| Thursday, October 4, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, October 22, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, October 22, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, October 22, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, November 20, 2018 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Monday, October 22, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, November 2, 2018 | ASSIGNED TO LIE |
| Tuesday, December 11, 2018 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Wednesday, December 19, 2018 | NON-FINAL ACTION WRITTEN |
| Wednesday, December 19, 2018 | NON-FINAL ACTION E-MAILED |
| Wednesday, December 19, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, December 20, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, December 20, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, December 21, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, December 22, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 9, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 29, 2019 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 29, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 26, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Friday, September 27, 2019 | TEAS PETITION TO REVIVE RECEIVED |
| Friday, September 27, 2019 | PETITION TO REVIVE-GRANTED |
| Friday, September 27, 2019 | SOU EXTENSION RECEIVED WITH TEAS PETITION |
| Monday, September 30, 2019 | NOTICE OF REVIVAL - E-MAILED |
| Thursday, September 26, 2019 | SOU EXTENSION 1 FILED |
| Tuesday, October 29, 2019 | SOU EXTENSION 1 GRANTED |
| Tuesday, October 29, 2019 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, October 30, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Saturday, March 28, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, March 26, 2020 | SOU TEAS EXTENSION RECEIVED |
| Thursday, March 26, 2020 | SOU EXTENSION 2 FILED |
| Thursday, March 26, 2020 | SOU EXTENSION 2 GRANTED |
| Monday, May 11, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, May 11, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, May 11, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, May 11, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, May 11, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, September 25, 2020 | SOU TEAS EXTENSION RECEIVED |
| Friday, September 25, 2020 | SOU EXTENSION 3 FILED |
| Friday, September 25, 2020 | SOU EXTENSION 3 GRANTED |
| Wednesday, November 25, 2020 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Sunday, September 5, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 29, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sunday, March 21, 2021 | SOU TEAS EXTENSION RECEIVED |
| Sunday, March 21, 2021 | SOU EXTENSION 4 FILED |
| Sunday, March 21, 2021 | SOU EXTENSION 4 GRANTED |
| Tuesday, March 23, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sunday, September 5, 2021 | SOU EXTENSION 5 FILED |
| Sunday, November 7, 2021 | USE AMENDMENT FILED |
| Wednesday, November 10, 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| Thursday, November 18, 2021 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Thursday, September 9, 2021 | SOU EXTENSION 5 GRANTED |
| Friday, September 10, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Saturday, October 16, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Saturday, October 16, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Saturday, October 16, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Sunday, November 7, 2021 | TEAS STATEMENT OF USE RECEIVED |
| Friday, November 19, 2021 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Monday, October 10, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, October 10, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, October 10, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, October 10, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, October 10, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, December 14, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Tuesday, December 21, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, March 9, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, May 25, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Thursday, June 23, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, December 28, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, September 10, 2025 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Friday, July 25, 2025 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, December 21, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, October 11, 2023 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |